{"entity":{"id":"nct07806058","kind":"trial","name":"An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of adebrelimab in pancreatic cancer, run by Jiangsu HengRui Medicine Co., Ltd., not yet recruiting.","summary":"An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors is a phase 1/2, randomised interventional study registered as NCT07806058 by Jiangsu HengRui Medicine Co., Ltd., with a registry enrolment figure of 140 participants, started 2026-09 and due to reach its primary completion in 2028-12-31. Interventions recorded: HRS-7172 + AG + SHR-1316; HRS-7172 + AG + SHR-1316;; HRS-7172 + AG;; HRS-7172 + AG + SHR-1316;; HRS-717 + HRS-4642+SHR-1316;; HRS-717 + HRS-4642+SHR-1316;; HRS-717 + HRS-4642;; HRS-717 + HRS-4642+SHR-1316;. Conditions listed: Pancreatic Cancer. Primary outcome: RDE in advanced pancreatic cancer with RAS mutation or amplification; Incidence and severity of adverse events (AEs) (per NCI-CTCAE V6.0 criteria); ORR assessed by the investigator. Pancreatic eligibility wording from the registry: \"Locally advanced or metastatic pancreatic cancer confirmed by histology and cytology, with RAS mutation/amplification detected by tissue or blood genetic testing\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07806058","url":"https://clinicaltrials.gov/study/NCT07806058"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["adebrelimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07806058","phase":"1/2","setting":"An Open-Label, Multicenter, Phase IB/II Clinical Study of the Safety, Tolerability, and Efficacy of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","enrolled":140,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07806058/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}